Physician profile
Mark Manning
NPI 1699171215
$8,988.48
in general payments reported to CMS, 2019-2025
30 companies · $1,853 in 2025
The $1,853 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,778 · 2022: $2,198 · 2023: $1,842 · 2024: $1,317 · 2025: $1,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,589 · Education: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,589.04 |
| Education | $422.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,813.85 | 2021-2025 | |
| Janssen Biotech, INC. | $1,493.16 | 2021-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $913.71 | 2021-2025 | |
| Genzyme Corporation | $509.12 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $437.55 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $383.11 | 2021-2024 | Absorica Ld, Winlevi, Ilumya |
| Janssen Scientific Affairs, LLC | $355.98 | 2021-2022 | |
| Pfizer INC. | $351.71 | 2021-2025 | |
| Allergan, INC. | $334.11 | 2021-2022 | |
| Incyte Corporation | $319.59 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $266.57 | 2022-2024 | Sotyktu |
| Ucb, INC. | $263.20 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $241.80 | 2021-2025 | Aklief, Nemluvio |
| Revance Therapeutics, INC. | $211.17 | 2025 | Daxxify |
| Lilly USA, LLC | $193.70 | 2021-2025 | Taltz, Olumiant, Ebglyss |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $133.36 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $114.81 | 2022 | |
| Mayne Pharma Commercial LLC | $109.98 | 2022-2025 | |
| Leo Pharma INC. | $92.71 | 2025 | Adbry, Anzupgo |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Mimedx Group, INC. | $75.37 | 2025 | |
| Genentech USA, INC. | $62.03 | 2021-2022 | |
| Amgen INC. | $57.53 | 2023 | Otezla |
| Kerecis Limited | $39.30 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Vyne Pharmaceuticals INC. | $37.80 | 2021 | |
| Dermavant Sciences, INC. | $34.95 | 2024 | Vtama |
| Abbott Laboratories | $18.28 | 2021 | |
| Sandoz INC. | $17.92 | 2025 | Hyrimoz |
| Verrica Pharmaceuticals INC. | $16.51 | 2025 | Ycanth |
| Organon LLC | $4.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Manning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.